JP2008534627A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008534627A5 JP2008534627A5 JP2008504532A JP2008504532A JP2008534627A5 JP 2008534627 A5 JP2008534627 A5 JP 2008534627A5 JP 2008504532 A JP2008504532 A JP 2008504532A JP 2008504532 A JP2008504532 A JP 2008504532A JP 2008534627 A5 JP2008534627 A5 JP 2008534627A5
- Authority
- JP
- Japan
- Prior art keywords
- amylin
- seq
- disorder
- disease
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000036849 Islet amyloid polypeptide Human genes 0.000 claims 59
- 108010041872 Islet amyloid polypeptide Proteins 0.000 claims 59
- 201000010099 disease Diseases 0.000 claims 27
- 239000000556 agonist Substances 0.000 claims 17
- 206010057666 Anxiety disease Diseases 0.000 claims 11
- 206010037175 Psychiatric disease Diseases 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 201000000980 schizophrenia Diseases 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 206010061284 Mental disease Diseases 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 102400000113 Calcitonin Human genes 0.000 claims 3
- 108060001064 Calcitonin Proteins 0.000 claims 3
- 229960004015 Calcitonin Drugs 0.000 claims 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical group N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 3
- 201000008895 mood disease Diseases 0.000 claims 3
- 201000008430 obsessive-compulsive disease Diseases 0.000 claims 3
- 206010012335 Dependence Diseases 0.000 claims 2
- 206010072387 Substance-induced mood disease Diseases 0.000 claims 2
- 231100000395 Substance-induced mood disorder Toxicity 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 201000009031 substance-related disease Diseases 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 1
- 201000006152 substance dependence Diseases 0.000 claims 1
Claims (24)
- 気分障害、不安障害または精神分裂病である精神の疾患または障害を治療するための配列番号：3、配列番号：33、配列番号：35、配列番号：67、配列番号：80、配列番号：81、配列番号：82および配列番号：83に記載の化合物よりなる群から選択されるアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体であって、
医薬が該疾患または障害を治療するために有効な量で投与され、アミリンアゴニストがカルシトニンではない該アミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体。 - 該疾患または障害が不安障害である、請求項１記載の精神の疾患または障害の治療のためのアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体。
- 該不安障害が強迫障害である、請求項２記載の精神の疾患または障害の治療のためのアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体。
- 疾患または障害が鬱病である、請求項１記載の精神の疾患または障害の治療のためのアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体。
- 疾患または障害が精神分裂病である、請求項１記載の精神の疾患または障害の治療のためのアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体。
- 該化合物が、配列番号：4-31、36-66および86-253よりなる群から選択される請求項１〜５のいずれか１記載のアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体。
- 請求項１〜５のいずれかのアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体を含む医薬上許容される組成物。
- 該アミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体が、配列番号：4-31、36-66および86-253よりなる群から選択される請求項６記載の医薬上許容される組成物。
- 気分障害、不安障害または精神分裂病である精神の疾患または障害を治療するための配列番号：3、配列番号：33、配列番号：35、配列番号：67、配列番号：80、配列番号：81、配列番号：82および配列番号：83に記載の化合物よりなる群から選択されるアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体を含む医薬組成物であって、
医薬が該疾患または障害を治療するために有効な量で投与され、アミリンアゴニストがカルシトニンではない該医薬組成物。 - 該疾患または障害が不安障害である請求項９記載の医薬組成物。
- 該不安障害が強迫障害である請求項１０記載の医薬組成物。
- 疾患または障害が鬱病である請求項９記載の医薬組成物。
- 疾患または障害が精神分裂病である請求項９記載の医薬組成物。
- 該アミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体が、配列番号：4-31、36-66および86-253よりなる群から選択される請求項９記載の医薬組成物。
- 気分障害、不安障害または精神分裂病である精神の疾患または障害の治療用医薬の製造のための配列番号：3、配列番号：33、配列番号：35、配列番号：67、配列番号：80、配列番号：81、配列番号：82および配列番号：83に記載の化合物よりなる群から選択されるアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体の使用であって、
医薬が該疾患または障害を治療するために有効な量で投与され、アミリンアゴニストがカルシトニンではないことを特徴とする該使用。 - 疾患または障害が不安障害であることを特徴とする請求項１５記載の使用。
- 不安障害が強迫障害であることを特徴とする請求項１６記載の使用。
- 疾患または障害が鬱病であることを特徴とする請求項１５記載の使用。
- 疾患または障害が精神分裂病であることを特徴とする請求項１５記載の使用。
- 少なくとも１つの他の精神医薬が対象に投与されることを特徴とする請求項１５記載の使用。
- 精神障害を治療用医薬の製造のための配列番号：3、配列番号：33、配列番号：35、配列番号：67、配列番号：80、配列番号：81、配列番号：82および配列番号：83に記載の化合物よりなる群から選択されるアミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体の使用であって、
医薬が該障害を治療するために有効な量で投与され、物質関連障害が、物質依存、物質嗜癖、物質誘導不安障害および物質誘導気分障害よりなる群から選択される該使用。 - 物質関連障害が、物質嗜癖、物質誘導不安障害または物質誘導気分障害であることを特徴とする請求項２１記載の使用。
- 少なくとも１つの他の精神医薬が対象に投与されることを特徴とする請求項２２記載の使用。
- 該アミリン、アミリンアゴニスト、アミリンアナログまたはアミリン誘導体が、配列番号：4-31、36-66および86-253よりなる群から選択されることを特徴とする請求項１５〜２３のいずれか１記載の使用。
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66733505P | 2005-03-31 | 2005-03-31 | |
| US66668105P | 2005-03-31 | 2005-03-31 | |
| US60/667,335 | 2005-03-31 | ||
| US60/666,681 | 2005-03-31 | ||
| US67544105P | 2005-04-28 | 2005-04-28 | |
| US60/675,441 | 2005-04-28 | ||
| US76058306P | 2006-01-20 | 2006-01-20 | |
| US60/760,583 | 2006-01-20 | ||
| PCT/US2006/012601 WO2006105527A2 (en) | 2005-03-31 | 2006-03-31 | Amylin and amylin agonists for treating psychiatric diseases and disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008534627A JP2008534627A (ja) | 2008-08-28 |
| JP2008534627A5 true JP2008534627A5 (ja) | 2009-05-21 |
| JP5114381B2 JP5114381B2 (ja) | 2013-01-09 |
Family
ID=37054153
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008504532A Expired - Fee Related JP5114381B2 (ja) | 2005-03-31 | 2006-03-31 | 精神疾患および障害治療用アミリンおよびアミリンアゴニスト |
| JP2008504396A Expired - Fee Related JP5415067B2 (ja) | 2005-03-31 | 2006-03-31 | 肥満および摂食障害の制御、防止および治療のための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008504396A Expired - Fee Related JP5415067B2 (ja) | 2005-03-31 | 2006-03-31 | 肥満および摂食障害の制御、防止および治療のための組成物および方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (7) | US7671023B2 (ja) |
| EP (5) | EP2258382A3 (ja) |
| JP (2) | JP5114381B2 (ja) |
| KR (3) | KR20080003849A (ja) |
| CN (3) | CN102343084A (ja) |
| AT (2) | ATE480255T1 (ja) |
| AU (2) | AU2006230420B2 (ja) |
| BR (2) | BRPI0606466A2 (ja) |
| CA (2) | CA2602584A1 (ja) |
| DE (2) | DE602006016760D1 (ja) |
| DK (1) | DK1888094T3 (ja) |
| EA (1) | EA013121B1 (ja) |
| ES (1) | ES2330671T3 (ja) |
| IL (1) | IL186200A (ja) |
| MX (2) | MX2007012236A (ja) |
| NZ (3) | NZ561936A (ja) |
| WO (2) | WO2006105527A2 (ja) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| US8114958B2 (en) * | 2004-02-11 | 2012-02-14 | Amylin Pharmaceuticals, Inc. | Amylin family peptides |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| AU2006230420B2 (en) * | 2005-03-31 | 2011-11-24 | Amylin Pharmaceuticals, Llc | Compositions and methods for the control, prevention, and treatment of obesity and eating disorders |
| EP1912666A2 (en) * | 2005-07-22 | 2008-04-23 | Amylin Pharmaceuticals, Inc. | Use of amylin and amylin agonists as cardioprotective or myoprotective agents |
| US8486890B2 (en) | 2006-03-15 | 2013-07-16 | Novo Nordisk A/S | Amylin derivatives |
| EP2010208A1 (en) * | 2006-03-31 | 2009-01-07 | Amylin Pharmaceuticals, Inc. | Amylin and amylin agonists for treating psychiatric diseases and disorders |
| US20090181890A1 (en) * | 2006-03-31 | 2009-07-16 | Amylin Pharmaceuticals , Inc. | Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders |
| DE602007009377D1 (de) | 2006-05-30 | 2010-11-04 | Intarcia Therapeutics Inc | Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem |
| US7682356B2 (en) | 2006-08-09 | 2010-03-23 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies for use therein |
| WO2008097536A2 (en) | 2007-02-05 | 2008-08-14 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating psychiatric diseases and disorders |
| JP5351884B2 (ja) | 2007-04-23 | 2013-11-27 | インターシア セラピューティクス，インコーポレイティド | インスリン分泌促進性ペプチドの懸濁製剤及び使用 |
| CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| CN102076353A (zh) * | 2008-06-25 | 2011-05-25 | 诺沃-诺迪斯克有限公司 | 胰岛淀粉样多肽和鲑鱼降钙素的衍生杂合肽 |
| WO2010046357A1 (en) * | 2008-10-21 | 2010-04-29 | Novo Nordisk A/S | Amylin derivatives |
| PL2373681T3 (pl) | 2008-12-10 | 2017-07-31 | Glaxosmithkline Llc | Kompozycje farmaceutyczne albiglutydu |
| JP5753097B2 (ja) * | 2009-01-22 | 2015-07-22 | ユニジーン・ラボラトリーズ・インコーポレーテッド | 肥満の治療 |
| US20120071401A1 (en) * | 2009-04-10 | 2012-03-22 | Amylin Pharamaceuticals, Inc. | Amylin agonist compounds for estrogen-deficient mammals |
| CA2758976C (en) | 2009-04-20 | 2015-02-03 | Alain Baron | Chemosensory receptor ligand-based therapies |
| US8828953B2 (en) * | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
| US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
| HUE035862T2 (en) | 2009-09-28 | 2018-05-28 | Intarcia Therapeutics Inc | Rapid development and / or completion of substantially steady-state drug delivery |
| US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
| US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
| WO2011140176A1 (en) | 2010-05-04 | 2011-11-10 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
| BRPI1005385A2 (pt) | 2010-06-28 | 2016-04-12 | Zte Corp | sistema de acesso integrado fechados e método de redução para o consumo de energia do mesmo |
| SG189444A1 (en) | 2010-10-19 | 2013-05-31 | Elcelyx Therapeutics Inc | Chemosensory receptor ligand-based therapies |
| SI2661266T1 (sl) | 2011-01-07 | 2021-01-29 | Anji Pharma (Us) Llc | Terapije, na osnovi kemosenzoričnih receptorskih ligandov |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| PH12018501119A1 (en) * | 2011-06-17 | 2019-02-04 | Hanmi Science Co Ltd | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
| MX2014008190A (es) | 2012-01-06 | 2015-02-04 | Elcelyx Therapeutics Inc | Composiciones de biguanida y métodos para tratar transtornos metabólicos. |
| KR101855242B1 (ko) * | 2012-01-26 | 2018-05-09 | 크리스토퍼 제이. 소레스 | 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도 |
| WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| BR102013017626A2 (pt) * | 2013-06-14 | 2015-02-10 | Univ Rio De Janeiro | Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças. |
| WO2015017455A1 (en) * | 2013-07-30 | 2015-02-05 | Soares Christopher J | Cgrp agonist peptides |
| AR097701A1 (es) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
| US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
| ES2968262T3 (es) | 2015-06-03 | 2024-05-08 | I2O Therapeutics Inc | Sistemas de colocación de implantes |
| WO2017200943A1 (en) | 2016-05-16 | 2017-11-23 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| WO2018045083A1 (en) | 2016-09-02 | 2018-03-08 | Soares Christopher J | Use of cgrp receptor antagonists in neuroprotection and neurological disorders |
| CN110225762A (zh) | 2017-01-03 | 2019-09-10 | 因塔西亚制药公司 | 包括glp-1受体激动剂的连续施用和药物的共同施用的方法 |
| CA3088131A1 (en) * | 2017-01-13 | 2018-07-19 | Pietro P. Sanna | Methods and compositions for treating hpa hyperactivity |
| EP3628233B1 (en) * | 2018-09-28 | 2021-06-02 | Siemens Healthcare GmbH | Method and system for providing a dose reference value for a patient |
| US11443843B2 (en) | 2019-01-04 | 2022-09-13 | International Business Machines Corporation | Personal customized guidance for treating patients |
| CN111700904A (zh) * | 2020-07-31 | 2020-09-25 | 江南大学 | 一种利用酰化淀粉定点释放短链脂肪酸的抗抑郁的方法 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0024807B1 (en) | 1979-07-28 | 1983-11-02 | Beecham Group Plc | Benzocycloheptapyrrolealkanoic acids and their derivatives, processes for their preparation and pharmaceutical compositions containing them |
| US4397780A (en) | 1982-02-12 | 1983-08-09 | Armour Pharmaceutical Company | Leucine22 -calcitonin |
| US4401593A (en) | 1982-02-12 | 1983-08-30 | Armour Pharmaceutical Company | Glycine - 8 calcitonin |
| US4414149A (en) | 1983-03-04 | 1983-11-08 | Armour Pharmaceutical Company | Glycine8 -D-arginine24 calcitonin |
| US4497731A (en) | 1983-04-04 | 1985-02-05 | Armour Pharmaceutical Company | Glycine 8-des-tyrosine 22 calcitonin |
| US4495097A (en) | 1983-04-04 | 1985-01-22 | Armour Pharmaceutical Company | Des-serine2 -glycine8 calcitonin |
| US4572208A (en) | 1983-06-29 | 1986-02-25 | Utah Medical Products, Inc. | Metabolic gas monitoring apparatus and method |
| US4597900A (en) | 1983-08-22 | 1986-07-01 | Armour Pharmaceutical Co. | Des2 -glycine8 -des22 -calcitonin |
| US4537716A (en) | 1983-12-05 | 1985-08-27 | Armour Pharmaceutical Co. | Des-serine2 or des-glycine2 -leucine22 calcitonin |
| FI78231C (fi) | 1984-11-21 | 1989-07-10 | Instrumentarium Oy | Maetanordning foer metaboliska storheter anslutbar till en respirator. |
| US4604238A (en) | 1984-12-10 | 1986-08-05 | Armour Pharmaceutical Company | Analogs of calcitonin |
| US4606856A (en) | 1985-03-18 | 1986-08-19 | Seyler Jay K | [Des-1-amino, 8-glycine]calcitonin |
| US4652627A (en) | 1985-08-16 | 1987-03-24 | Kempe Tomas G | Calcitonin analogs with C-terminal D-amino acid substituents |
| US4697002A (en) | 1985-12-23 | 1987-09-29 | Kempe Tomas G | Calcitonin gene related peptide analogs with amino acid subdstituents at the penultimate position 36 |
| US4687839A (en) | 1985-12-23 | 1987-08-18 | Kempe Tomas G | Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents |
| GB8709871D0 (en) | 1987-04-27 | 1987-06-03 | Turner R C | Peptides |
| US5175145A (en) | 1988-08-26 | 1992-12-29 | Amylin Pharmaceuticals, Inc. | Treatment of diabetes mellitus with amylin agonists |
| CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
| US5405831A (en) | 1989-07-08 | 1995-04-11 | Amylin Pharmaceuticals, Inc. | Treatment of bone disorders |
| US5234906A (en) | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
| US5264372A (en) | 1991-03-15 | 1993-11-23 | Amylin Pharmaceuticals, Inc. | Receptor-based screening methods for amylin agonists and antagonists |
| HU222249B1 (hu) * | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
| DK0567626T3 (da) * | 1991-11-19 | 2001-12-17 | Amylin Pharmaceuticals Inc | Amylin-agonist-peptider og anvendelse deraf |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US6174530B1 (en) | 1993-05-05 | 2001-01-16 | Gryphon Sciences | Homogeneous polyoxime compositions and their preparation by parallel assembly |
| US6001364A (en) | 1993-05-05 | 1999-12-14 | Gryphon Sciences | Hetero-polyoxime compounds and their preparation by parallel assembly |
| US5589356A (en) | 1993-06-21 | 1996-12-31 | Vanderbilt University | Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement |
| RU2177331C2 (ru) | 1993-09-07 | 2001-12-27 | Амилин Фармасьютикалз, Инк. | Способы регулирования моторики желудочно-кишечного тракта |
| US5766627A (en) | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6184344B1 (en) | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
| US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
| US6013009A (en) | 1996-03-12 | 2000-01-11 | Karkanen; Kip Michael | Walking/running heart rate monitoring system |
| US5677279A (en) | 1996-12-16 | 1997-10-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating pain with amylin or agonists thereof |
| US6307018B1 (en) | 1996-12-24 | 2001-10-23 | The Scripps Research Institute | General chemical ligation |
| WO1998030231A1 (en) * | 1997-01-07 | 1998-07-16 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
| US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6309360B1 (en) | 1997-03-17 | 2001-10-30 | James R. Mault | Respiratory calorimeter |
| US7101853B2 (en) | 1997-05-06 | 2006-09-05 | Amylin Pharmaceuticals, Inc. | Method for treating or preventing gastritis using amylin or amylin agonists |
| US20040022807A1 (en) | 1998-06-05 | 2004-02-05 | Duft Bradford J | Methods for treating obesity |
| DE69828287T2 (de) | 1997-06-13 | 2005-12-15 | Gryphon Therapeutics, Inc., South San Francisco | Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen |
| US6538194B1 (en) | 1998-05-29 | 2003-03-25 | Catalysts & Chemicals Industries Co., Ltd. | Photoelectric cell and process for producing metal oxide semiconductor film for use in photoelectric cell |
| US6087334A (en) | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
| US6451543B1 (en) | 1998-08-31 | 2002-09-17 | Gryphon Sciences | Lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides |
| US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| TW514510B (en) | 1999-06-11 | 2002-12-21 | Tanita Seisakusho Kk | Method and apparatus for measuring distribution of body fat |
| US6468222B1 (en) | 1999-08-02 | 2002-10-22 | Healthetech, Inc. | Metabolic calorimeter employing respiratory gas analysis |
| US6530886B1 (en) | 1999-10-08 | 2003-03-11 | Tanita Corporation | Method and apparatus for measuring subcutaneous fat using ultrasonic wave |
| US6264987B1 (en) | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
| TW515705B (en) | 2000-05-31 | 2003-01-01 | Yamato Scale Co Ltd | Visceral fat meter |
| US6296842B1 (en) | 2000-08-10 | 2001-10-02 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
| US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
| HUP0303854A2 (hu) | 2000-09-08 | 2004-03-01 | Gryhon Therapeutics, Inc. | Szintetikus erythropoiesis-stimuláló proteinek |
| US6475158B1 (en) | 2000-10-24 | 2002-11-05 | Korr Medical Technologies, Inc. | Calorimetry systems and methods |
| GB0113657D0 (en) | 2001-06-05 | 2001-07-25 | Geneprot Inc | Improved native chemical ligation with three or more components |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| US20040138412A1 (en) | 2001-09-07 | 2004-07-15 | Paolo Botti | Extended native chemical ligation |
| CA2466746A1 (en) | 2001-11-14 | 2003-05-22 | Geneprot, Inc. | Extended native chemical ligation of three or more peptide fragments |
| WO2003057244A2 (en) | 2002-01-08 | 2003-07-17 | Amylin Pharmaceuticals, Inc. | Use of amylin agonists to modulate triglycerides |
| AR040126A1 (es) * | 2002-05-29 | 2005-03-16 | Glaxo Group Ltd | Compuesto de fenilsulfonilo, composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento |
| US7566697B2 (en) | 2002-06-10 | 2009-07-28 | Amylin Pharmaceuticals, Inc. | Carboxy protection strategies for acidic C-terminal amino acids in chemical ligation of oligopeptides |
| US6965013B2 (en) | 2002-11-26 | 2005-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | Intermedin and its uses |
| WO2004060925A2 (en) | 2002-12-30 | 2004-07-22 | Gryphon Therapeutics, Inc. | Multiplex polymer ligation |
| US20040197287A1 (en) * | 2003-04-04 | 2004-10-07 | The Procter & Gamble Company | Personal care composition containing an antidandruff component and a nonionic surfactant |
| EP1631597A4 (en) | 2003-05-22 | 2007-07-11 | Gryphon Therapeutics Inc | SOLID PHASE CHEMICAL LIGATION CARRIED OUT WITH A MOBILE BONDING AGENT |
| US8114958B2 (en) | 2004-02-11 | 2012-02-14 | Amylin Pharmaceuticals, Inc. | Amylin family peptides |
| US7399744B2 (en) | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
| BRPI0516574A (pt) | 2004-10-08 | 2008-09-16 | Amylin Pharmaceuticals Inc | análogos do polipeptìdeo-6 da famìlia amilina (afp-6) e métodos para preparar e usar os mesmos |
| AU2006230420B2 (en) | 2005-03-31 | 2011-11-24 | Amylin Pharmaceuticals, Llc | Compositions and methods for the control, prevention, and treatment of obesity and eating disorders |
-
2006
- 2006-03-31 AU AU2006230420A patent/AU2006230420B2/en not_active Ceased
- 2006-03-31 AU AU2006230602A patent/AU2006230602B2/en not_active Ceased
- 2006-03-31 NZ NZ561936A patent/NZ561936A/en not_active IP Right Cessation
- 2006-03-31 EP EP10008998.6A patent/EP2258382A3/en not_active Withdrawn
- 2006-03-31 EP EP06749305A patent/EP1888094B1/en active Active
- 2006-03-31 KR KR1020077025124A patent/KR20080003849A/ko active IP Right Grant
- 2006-03-31 CN CN2011102204917A patent/CN102343084A/zh active Pending
- 2006-03-31 MX MX2007012236A patent/MX2007012236A/es active IP Right Grant
- 2006-03-31 DK DK06749305T patent/DK1888094T3/da active
- 2006-03-31 JP JP2008504532A patent/JP5114381B2/ja not_active Expired - Fee Related
- 2006-03-31 EP EP10008733A patent/EP2248527A3/en not_active Withdrawn
- 2006-03-31 BR BRPI0606466-3A patent/BRPI0606466A2/pt not_active IP Right Cessation
- 2006-03-31 MX MX2007012237A patent/MX2007012237A/es active IP Right Grant
- 2006-03-31 EA EA200702126A patent/EA013121B1/ru not_active IP Right Cessation
- 2006-03-31 EP EP09009392.3A patent/EP2135617A3/en not_active Withdrawn
- 2006-03-31 ES ES06749305T patent/ES2330671T3/es active Active
- 2006-03-31 US US11/910,206 patent/US7671023B2/en not_active Expired - Fee Related
- 2006-03-31 NZ NZ578298A patent/NZ578298A/en not_active IP Right Cessation
- 2006-03-31 DE DE602006016760T patent/DE602006016760D1/de active Active
- 2006-03-31 CN CN2006800192236A patent/CN101189021B/zh not_active Expired - Fee Related
- 2006-03-31 AT AT06740117T patent/ATE480255T1/de not_active IP Right Cessation
- 2006-03-31 BR BRPI0609595A patent/BRPI0609595A8/pt not_active IP Right Cessation
- 2006-03-31 AT AT06749305T patent/ATE439140T1/de active
- 2006-03-31 KR KR1020137025456A patent/KR20130122983A/ko not_active Application Discontinuation
- 2006-03-31 WO PCT/US2006/012601 patent/WO2006105527A2/en active Application Filing
- 2006-03-31 EP EP06740117A patent/EP1871403B1/en active Active
- 2006-03-31 US US11/910,214 patent/US7879794B2/en not_active Expired - Fee Related
- 2006-03-31 KR KR1020077025152A patent/KR101383493B1/ko not_active IP Right Cessation
- 2006-03-31 CA CA002602584A patent/CA2602584A1/en not_active Abandoned
- 2006-03-31 JP JP2008504396A patent/JP5415067B2/ja not_active Expired - Fee Related
- 2006-03-31 WO PCT/US2006/011768 patent/WO2006105345A2/en active Application Filing
- 2006-03-31 NZ NZ578299A patent/NZ578299A/en not_active IP Right Cessation
- 2006-03-31 DE DE602006008456T patent/DE602006008456D1/de active Active
- 2006-03-31 CA CA002602261A patent/CA2602261A1/en not_active Abandoned
- 2006-10-04 CN CNA2006800541222A patent/CN101415435A/zh active Pending
-
2007
- 2007-09-24 IL IL186200A patent/IL186200A/en not_active IP Right Cessation
-
2009
- 2009-12-18 US US12/641,733 patent/US20100125054A1/en not_active Abandoned
-
2010
- 2010-12-09 US US12/964,516 patent/US8278267B2/en not_active Expired - Fee Related
-
2011
- 2011-05-20 US US13/112,290 patent/US8389477B2/en not_active Expired - Fee Related
-
2012
- 2012-09-28 US US13/631,577 patent/US20130225485A1/en not_active Abandoned
-
2013
- 2013-02-26 US US13/777,149 patent/US20130184213A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008534627A5 (ja) | ||
| JP2019031502A5 (ja) | ||
| Bourne et al. | Sleep disruption in critically ill patients–pharmacological considerations | |
| JP2007504174A5 (ja) | ||
| JP2010535252A5 (ja) | ||
| JP2014517050A5 (ja) | ||
| JP2008538582A (ja) | 精神病性障害の治療または予防のための新規の治療的組み合わせ | |
| JP2010529118A5 (ja) | ||
| JP2007523168A5 (ja) | ||
| HRP20120264T1 (hr) | Farmaceutski sastavi neuroaktivnog steroida i njihove uporabe | |
| MY147442A (en) | Imidazoquinolines as lipid kinase inhibitors | |
| DE602005026007D1 (de) | Opioide zur behandlung von chronisch-obstruktiver lungenerkrankung (copd) | |
| JP2005500357A5 (ja) | ||
| NO20092231L (no) | Arylvinylazasykloalkan-forbindelser og fremgangsmater for deres fremstilling og anvendelse derav | |
| CN100586945C (zh) | 取代的1-哌啶-4-基-4-吡咯烷-3-基哌嗪衍生物及其作为神经激肽拮抗剂的用途 | |
| HRP20120144T1 (en) | Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity | |
| JP2008535785A5 (ja) | ||
| DE602004024565D1 (de) | Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems | |
| JP2007516193A5 (ja) | ||
| JP2011507861A5 (ja) | ||
| JP2011500673A5 (ja) | ||
| MX2010009643A (es) | Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a). | |
| JP2008519056A5 (ja) | ||
| JP2022180531A5 (ja) | ||
| JP2007509960A5 (ja) |